Higher baseline coffee consumption also linked to slower A\u03b2-amyloid accumulation during a 126-month study period as shown on brain MRI scans<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 30, 2021 (HealthDay News) — For cognitively normal older adults, increased coffee consumption is associated with slower cognitive decline and a lower likelihood of transitioning to mild cognitive impairment or Alzheimer disease (AD) status, according to a study published online Nov. 19 in Frontiers in Aging Neuroscience<\/em>.<\/p>\n Samantha L. Gardener, Ph.D., from Edith Cowan University in Joondalup, Australia, and colleagues examined the association between self-reported habitual coffee intake and cognitive decline examined during a period of 126 months using a comprehensive battery of neuropsychological tests among 227 cognitively normal older adults from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study. In a subset of participants, the association between habitual coffee intake and cerebral A\u00ce\u00b2-amyloid accumulation and brain volumes was examined (60 and 51 participants, respectively).<\/p>\n The researchers found that higher baseline coffee consumption was associated with slower cognitive decline in executive function, attention, and the AIBL Preclinical AD Cognitive Composite over 126 months and with a lower likelihood of transitioning to mild cognitive impairment or AD status. There was also an association observed for higher baseline coffee consumption with slower A\u00ce\u00b2-amyloid accumulation during the study period and with a lower risk of progressing to moderate, high, or very high A\u00ce\u00b2-amyloid burden status.<\/p>\n “[This research] could be particularly useful for people who are at risk of cognitive decline but haven’t developed any symptoms,” Gardener said in a statement. “We might be able to develop some clear guidelines people can follow in middle age and hopefully it could then have a lasting effect.”<\/p>\n Several authors disclosed financial ties to pharmaceutical and biotechnology companies.<\/p>\n